Affiliation:
1. HairClone, 70 Quay St, Manchester, M3 3EJ, UK
Abstract
The last decade has seen considerable changes in the Regenerative Medicine industry, but unfortunately the hope for numerous treatments that ‘replace or regenerate human cells, tissues or organs to restore or establish normal function’ has not yet emerged. In contrast to this, there have been major advances in the field of cellular immunotherapy though some do not consider these to be Regenerative Medicines. Regulatory changes have in some cases improved the route to a marketing license but they have not been matched by clarification of the complex, national reimbursement processes for cell-based treatments and this has adversely affected a number of leading Regenerative Medicine Companies. The review considers the direction that the industry may go in the future in relation to scientific, manufacturing and clinical strategies which may improve the rate of success of new therapies..
Subject
Embryology,Biomedical Engineering
Reference38 articles.
1. Tigenix Press Release July 5 2016. Takeda and TiGenix Enter into Licensing Agreement for Ex-U.S. rights to Cx601 for the Treatment of Complex Perianal Fistulas in Patients with Crohn's Disease. www.tigenix.com/en/pages/11/2016.
2. Evaluation of ApligrafR persistence and basement membrane restoration in donor site wounds: a pilot study
3. History of regenerative medicine: looking backwards to move forwards
4. Source: Curis, Inc. Announces Sale of its BMP-7 Assets to Stryker Corporation. Press release: http://investors.curis.com/releasedetail.cfm?releaseid=633387.
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献